

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Vemircopan (Synonyms: ALXN2050; ACH 0145228; ACH-5228)

Cat.No. :URK-V2533 **CAS No.** :2086178-00-7

 $\begin{tabular}{ll} \textbf{Molecular Weight} & :602.48 \\ \textbf{Molecular Formula} & :C_{29}H_{28}BrN_7O_3 \\ \end{tabular}$

Target : Solubility :

H N O HN N B

Biological Activity

Vemircopan (Synonyms: ALXN2050; ACH 0145228; ACH-5228) is a novel small-molecule inhibitor that targets complement protein C5a.

C5a is a pro-inflammatory protein that plays a critical role in the activation of the complement system. It has been implicated in a variety of autoimmune and inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, and atypical hemolytic uremic syndrome. By targeting C5a, Vemircopan has the potential to reduce inflammation and tissue damage associated with these diseases.

In vitro and in vivo studies have shown that Vemircopan is a highly potent and selective inhibitor of C5a. It has demonstrated strong binding affinity for C5a and has been shown to inhibit its biological activity in both human and mouse cells. In preclinical models of inflammatory and autoimmune diseases, Vemircopan has shown significant efficacy in reducing inflammation and tissue damage.

Vemircopan is currently in phase 2 clinical trials for the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. Preliminary results from these trials have shown promising efficacy and safety profiles. Further clinical trials are planned to assess the potential of Vemircopan in treating other inflammatory and autoimmune diseases.

References

- 1. K. Ricklin, J.D. Lambris, Nat Rev Drug Discov. 2021 Feb; 20(2):123-144.
- 2. Alexion Pharmaceuticals, Inc. Pipeline. Accessed on 8/16/2021.

<u>Note:All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide</u> products and services for any personal use!